323 related articles for article (PubMed ID: 9247523)
21. Metoprolol versus sotalol in the treatment of sustained ventricular tachycardia.
Antz M; Cappato R; Kuck KH
J Cardiovasc Pharmacol; 1995 Oct; 26(4):627-35. PubMed ID: 8569226
[TBL] [Abstract][Full Text] [Related]
22. Electrophysiologic mechanisms of antiarrhythmic efficacy of a sotalol and class Ia drug combination: elimination of reverse use dependence.
Lee SD; Newman D; Ham M; Dorian P
J Am Coll Cardiol; 1997 Jan; 29(1):100-5. PubMed ID: 8996301
[TBL] [Abstract][Full Text] [Related]
23. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
Finance O; Manning A; Chatelain P
J Cardiovasc Pharmacol; 1995 Oct; 26(4):570-6. PubMed ID: 8569217
[TBL] [Abstract][Full Text] [Related]
24. Electrophysiologic and antiarrhythmic effects of sotalol in patients with life-threatening ventricular tachyarrhythmias.
Nademanee K; Feld G; Hendrickson J; Singh PN; Singh BN
Circulation; 1985 Sep; 72(3):555-64. PubMed ID: 4017207
[TBL] [Abstract][Full Text] [Related]
25. Antiarrhythmic actions of amiodarone: a profile of a paradoxical agent.
Singh BN
Am J Cardiol; 1996 Aug; 78(4A):41-53. PubMed ID: 8780328
[TBL] [Abstract][Full Text] [Related]
26. Sotalol in patients with life-threatening ventricular tachyarrhythmias.
Trappe HJ; Klein H; Lichtlen P
Cardiovasc Drugs Ther; 1990 Oct; 4(5):1425-32. PubMed ID: 2278875
[TBL] [Abstract][Full Text] [Related]
27. A new biomarker--index of cardiac electrophysiological balance (iCEB)--plays an important role in drug-induced cardiac arrhythmias: beyond QT-prolongation and Torsades de Pointes (TdPs).
Lu HR; Yan GX; Gallacher DJ
J Pharmacol Toxicol Methods; 2013; 68(2):250-259. PubMed ID: 23337247
[TBL] [Abstract][Full Text] [Related]
28. [Antiarrhythmia effectiveness of oral sotalol in patients with coronary heart disease and ventricular tachycardias].
Trappe HJ; Klein H; Lichtlen PR
Z Kardiol; 1987 Oct; 76(10):630-4. PubMed ID: 3687165
[TBL] [Abstract][Full Text] [Related]
29. Effects of sotalol and d-sotalol on ventricular tachycardia and fibrillation induced by programmed electrical stimulation.
Aliot E; Sadoul N; De Chillou C
Eur Heart J; 1993 Nov; 14 Suppl H():74-7. PubMed ID: 7904940
[TBL] [Abstract][Full Text] [Related]
30. Enhanced efficacy of oral sotalol for sustained ventricular tachycardia refractory to type I antiarrhythmic drugs.
Kienzle MG; Martins JB; Wendt DJ; Constantin L; Hopson R; McCue ML
Am J Cardiol; 1988 May; 61(13):1012-7. PubMed ID: 3129926
[TBL] [Abstract][Full Text] [Related]
31. The role of EP-guided therapy in ventricular arrhythmias: beta-blockers, sotalol, and ICD's.
Capucci A; Aschieri D; Villani GQ
J Interv Card Electrophysiol; 2000 Jan; 4 Suppl 1():57-63. PubMed ID: 10590490
[TBL] [Abstract][Full Text] [Related]
32. From first class to third class: recent upheaval in antiarrhythmic therapy--lessons from clinical trials.
Lazzara R
Am J Cardiol; 1996 Aug; 78(4A):28-33. PubMed ID: 8780326
[TBL] [Abstract][Full Text] [Related]
33. Risk stratification and clinical outcome of minimally symptomatic and asymptomatic patients with nonsustained ventricular tachycardia and coronary disease: a prospective single-center study.
Giorgberidze I; Saksena S; Krol RB; Munsif AN; Kolettis T; Mathew P; Varanasi S; Prakash A; Delfaut P; Lewis CB
Am J Cardiol; 1997 Sep; 80(5B):3F-9F. PubMed ID: 9291444
[TBL] [Abstract][Full Text] [Related]
34. Torsade de pointes secondary to d,l-sotalol after catheter ablation of incessant atrioventricular reentrant tachycardia--evidence for a significant contribution of the "cardiac memory".
Haverkamp W; Hördt M; Breithardt G; Borggrefe M
Clin Cardiol; 1998 Jan; 21(1):55-8. PubMed ID: 9474467
[TBL] [Abstract][Full Text] [Related]
35. Clinical usefulness of electrophysiologic testing in patients with ventricular tachycardia and chronic chagasic cardiomyopathy treated with amiodarone or sotalol.
Leite LR; Fenelon G; Simoes A; Silva GG; Friedman PA; de Paola AA
J Cardiovasc Electrophysiol; 2003 Jun; 14(6):567-73. PubMed ID: 12875414
[TBL] [Abstract][Full Text] [Related]
36. Sotalol and type IA drugs in combination prevent recurrence of sustained ventricular tachycardia.
Dorian P; Newman D; Berman N; Hardy J; Mitchell J
J Am Coll Cardiol; 1993 Jul; 22(1):106-13. PubMed ID: 8509529
[TBL] [Abstract][Full Text] [Related]
37. Sotalol: An important new antiarrhythmic.
Anderson JL; Prystowsky EN
Am Heart J; 1999 Mar; 137(3):388-409. PubMed ID: 10047618
[TBL] [Abstract][Full Text] [Related]
38. Comparison of metoprolol and sotalol in preventing ventricular tachyarrhythmias after the implantation of a cardioverter/defibrillator.
Seidl K; Hauer B; Schwick NG; Zahn R; Senges J
Am J Cardiol; 1998 Sep; 82(6):744-8. PubMed ID: 9761084
[TBL] [Abstract][Full Text] [Related]
39. Sotalol for refractory sustained ventricular tachycardia and nonfatal cardiac arrest.
Singh SN; Cohen A; Chen YW; Wish M; Thoben-O'Grady L; Peralba J; Gottdiener J; Fletcher RD
Am J Cardiol; 1988 Sep; 62(7):399-402. PubMed ID: 2458026
[TBL] [Abstract][Full Text] [Related]
40. Electrocardiographic predictors in the ESVEM trial: unsustained ventricular tachycardia, heart period variability, and the signal-averaged electrocardiogram.
Anderson KP; Bigger JT; Freedman RA
Prog Cardiovasc Dis; 1996; 38(6):463-88. PubMed ID: 8638028
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
